(openPR) - Orlando, FL – ZYTO Corp. (Pink Sheets: ZYTC) has added the newest weight loss product from XYMOGEN Inc. to ZYTO technology used by health care practitioners to help their patients obtain better health.
“We congratulate XYMOGEN for the introduction of fitfood (tm). We know that healthcare practitioners will be pleased with this new product they can use in conjunction with ZYTO technology as they work to help people who want to lose weight and get fit,” said Dr. Vaughn R. Cook, OMD, president and founder of Zyto Corp.
XYMOGEN and ZYTO have a strategic marketing alliance which enables XYMOGEN to sell ZYTO bio-technology to healthcare practitioners who use XYMOGEN formulas for their patients or clients.
XYMOGEN is a leading provider of research-based, high-quality, nutraceuticals and functional foods exclusively to licensed healthcare professionals, according to Brian Blackburn, C.E.O. and XYMOGEN co-founder.
“Losing weight is not just about weighing less. It’s about maintaining and building lean muscle mass as fat melts away, supporting immune health, optimizing gastrointestinal health and function, promoting cardiovascular wellness, and supporting the proper conversion of food into energy,” explained Blackburn.
XYMOGEN’s newest product, fitfood, is designed to be used along with a personalized food and nutritional supplement program. Healthcare practitioners might suggest fitfood for breakfast and lunch, along with fruit and perhaps vegetables, then “regular” food for dinner, Blended with water or other liquid recommended by the practitioner, fitfood may be used as a partial or complete meal replacement, according to Blackburn.
ZYTO Corp. was founded by Dr. Vaughn Cook, OMD. The company provides computerized bio-technology equipment and software with clinical applications that include obtaining information from the human body to assist healthcare practitioners to make better decisions.
Forward Looking Statement:
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports the Company may file.
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
Newsfeed
